Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — April 2024

Genmab — April 2024

Planlagt Fastgjort Låst Flyttet Genmab
759 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • K Offline
    K Offline
    Klarussen
    wrote on sidst redigeret af
    #649

    Det er diskutabelt 🙂

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #650

      Jan is in China https://www.suzhou.gov.cn/szsrmzf/szyw/202404/cca1b7c983244a14a45bd19455bc1b98.shtml

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #651

        Teknisk: Det endelige positive brud lader vente på sig for Genmab https://ugebrev.dk/flashnews/teknisk-det-endelige-positive-brud-lader-vente-paa-sig-for-genmab/ - i draw my lines a bit different, but it is an opinion..

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #652

          Goldman Sachs sänker riktkursen för Genmab till 2 218 danska kronor (2 284), upprepar neutral - BN (Finwire)
          2024-04-25 06:30 https://www.placera.se/placera/telegram/2024/04/25/genmab-goldman-sachs-sanker-riktkursen-for-genmab-till-2-218-danska-kronor-2-284-upprepar-neutral-bn.html

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #653

            Sanofi Sarclisa Q1 '24 €106mn https://ml-eu.globenewswire.com/Resource/Download/ca345f70-58d6-4aa7-a4b1-8b6b43551051

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #654

              Keytruda sales
              $

              6,947 . for 1 quarter...

              1 Reply Last reply
              0
              • SolsenS Offline
                SolsenS Offline
                Solsen
                wrote on sidst redigeret af
                #655

                Spectacular !

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #656

                  this may be useful for future
                  Congress Presentations - hint you are a US healthcare professional 😉 https://www.genmabmedicalaffairs.com/congress

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #657

                    new trial - A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/​Metastatic Head and Neck Cancer (OrigAMI-4) https://clinicaltrials.gov/study/NCT06385080

                    1 Reply Last reply
                    0
                    • P Offline
                      P Offline
                      ProinvestorNEWS
                      wrote on sidst redigeret af
                      #658

                      Kort video..Der er kommet Q1-regnskab fra flere amerikanske selskaber. Bl.a. Tesla, IBM og Meta. Fedmeaktierne Novo Nordisk, Eli Lilly og Zealand Pharma falder efter kritik i USA af prissætningen på fedmeprodukter. Genmab falder også, efter to banker sænker kursmålet. https://www.proinvestor.com/boards/120115/

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #659

                        Regarding GEN1046 at ASCO - not impressed if its only a poster.

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #660

                          i was thinking the same to be honest...

                          1 Reply Last reply
                          0
                          • L Offline
                            L Offline
                            LP90
                            wrote on sidst redigeret af
                            #661

                            Aktien har det godt nok svær

                            1 Reply Last reply
                            0
                            • L Offline
                              L Offline
                              LP90
                              wrote on sidst redigeret af
                              #662

                              Godmorgen 🙂 det gode ved aktien er faldet så meget er at den jo så også kan stige meget 🙂

                              1 Reply Last reply
                              0
                              • W Offline
                                W Offline
                                w
                                wrote on sidst redigeret af
                                #663

                                jo længere ned den kommer,
                                jo flere aktier kan ledelsen ta' ud af markedet

                                1 Reply Last reply
                                0
                                • W Offline
                                  W Offline
                                  w
                                  wrote on sidst redigeret af
                                  #664

                                  Jeg faldt over Roei Mazor's kommentar på linkedin i forbindelse med FDA's mrd beslutning og hvad det kunne medføre for hexCD38: "Fascinating to see this asset in action".

                                  1 Reply Last reply
                                  0
                                  • W Offline
                                    W Offline
                                    w
                                    wrote on sidst redigeret af
                                    #665

                                    tester han stoffet på sin klinik?

                                    1 Reply Last reply
                                    0
                                    • J Offline
                                      J Offline
                                      JKY_VH
                                      wrote on sidst redigeret af
                                      #666

                                      Pas, men et eller andet har han jo tydeligvis set.

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #667

                                        Roche Q1 '24 Lunsumio CHF16mn Columvi CHF 25mn

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #668

                                          AbbVie Epkinly US $12, Intern. $15, Total $27. Epkinly U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain
                                          international territories

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper